This is a preview of subscription content, log in via an institution to check access.
Reference
Saiyed M, et al. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia. Clinical Drug Investigation : 2 Nov 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00983-7
Rights and permissions
About this article
Cite this article
Lenvatinib cost effective in advanced liver cancer in Australia. PharmacoEcon Outcomes News 866, 22 (2020). https://doi.org/10.1007/s40274-020-7282-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7282-7